Try our mobile app

Published: 2021-05-04 08:10:31 ET
<<<  go to SPNS company page
EX-99.1 2 ea140292ex99-1_sapiensinter.htm PRESS RELEASE

Exhibit 99.1

 

 

 

Sapiens Reports First Quarter 2021 Financial Results

 

Holon, Israel, May 4, 2021Sapiens International Corporation, (NASDAQ and TASE: SPNS), a leading global provider of software solutions for the insurance industry, today announced its financial results for the first quarter ended March 31, 2021.

 

Summary Results for First Quarter 2021 (USD in millions, except per share data)

 

   GAAP       Non-GAAP     
   Q1 2021   Q1 2020    % Change   Q1 2021    Q1 2020    % Change 
Revenue  $109.6   $90.5    21.1%  $110.2   $90.5    21.7%
Gross Profit  $44.3   $36.3    22.0%  $49.2   $39.8    23.7%
Gross Margin   40.4%   40.1%   30bps   44.7%   44.0%   70bps
Operating Income  $12.4   $10.3    20.3%  $19.0   $14.6    30.0%
Operating Margin   11.3%   11.4%   (10)bps   17.2%   16.1%   110bps
Net Income (*)  $9.8   $6.8    44.2%  $14.9   $10.4    43.2%
Diluted EPS  $0.18   $0.13    38.5%  $0.27   $0.20    35.0%

 

(*)Attributable to Sapiens’ shareholders.

 

“Our revenue growth in the first quarter validates our strategy of building global diversity with a broad business portfolio, which provides the foundation for Sapiens’ performance and growth. Solid execution in the first quarter delivered 22% non-GAAP revenue growth, with non-GAAP revenues reaching a record $110 million and non-GAAP operating margin increasing to 17.2% from 16.1%. Our growth in the first quarter originated primarily from Europe and Rest-of-the-World. Operating a global company across multiple insurance markets and deploying a diversified product offering allows us to balance our growth, resources, investments, and risks across regions and markets. With a strategic focus and the increasing global market demand for digital insurance solutions and transformations, Sapiens is well positioned for continued financial performance,” said Roni Al-Dor, Sapiens president and CEO.

 

“We are increasing our 2021 revenue guidance to a range of $459 to $464 million from our prior range of $457 to $463 million. We are also updating our operating profit margin guidance, due to our plan initiated this quarter to manage our growth and investment in delivery capabilities in the North American P&C CoreSuite business, and following the recent spike in COVID-19 in India, which will increase our labor costs in the short term. As a result of these two factors, operating margin in 2021 is expected to be in the range of 17.0% to 17.4% compared to the previous range of 17.7% to 18.0%. I would like to highlight that Sapiens remains committed to increasing its profitability and margins, as we have done year after year.”

 

Quarterly Results Conference Call

 

Management will host a conference call and webcast today, May 4, 2021 at 9:30 a.m. Eastern Time (4:30 p.m. in Israel) to review and discuss Sapiens’ results.

 

Please call the following numbers (at least 10 minutes before the scheduled time) to participate:

North America (toll-free): + 1-888- 642-5032; International: +972-3-918-0609; UK: 0-800-917-5108.

 

The live webcast of the call can be accessed on Sapiens’ website at https://www.sapiens.com/investor-relations/ir-events-presentations/. A replay of the call will be available one business day following the completion of the event at the same location for 90 days.

 

1

 

 

Non-GAAP Financial Measures

 

This press release contains the following non-GAAP financial measures: non-GAAP revenue, non-GAAP gross profit, non-GAAP operating income, non-GAAP net income attributed to Sapiens shareholders, non-GAAP basic and diluted earnings per share, Adjusted EBITDA and Adjusted Free Cash-Flow.

 

Sapiens believes that these non-GAAP measures of financial results provide useful information to management and investors regarding certain financial and business trends relating to Sapiens’ financial condition and results of operations. The Company’s management uses these non-GAAP measures to compare the Company’s performance to that of prior periods for trend analyses, for purposes of determining executive and senior management incentive compensation and for budgeting and planning purposes. These measures are used in financial reports prepared for management and in quarterly financial reports presented to the Company’s board of directors. The Company believes that the use of these non-GAAP financial measures provides an additional tool for investors to use in evaluating ongoing operating results and trends, and in comparing the Company’s financial measures with other software companies, many of which present similar non-GAAP financial measures to investors.

 

Non-GAAP financial measures consist of GAAP financial measures adjusted to exclude: Valuation adjustment on acquired deferred revenue, amortization of capitalized software development and other intangible assets, capitalization of software development, stock-based compensation, compensation related to acquisition and acquisition-related costs, restructuring and cost reduction costs, and tax adjustments related to non-GAAP adjustments.

 

Management of the Company does not consider these non-GAAP measures in isolation, or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of these non-GAAP financial measures is that they exclude significant expenses and income that are required by GAAP to be recorded in the Company’s financial statements. In addition, they are subject to inherent limitations, as they reflect the exercise of judgment by management about which expenses and income are excluded or included in determining these non-GAAP financial measures.

 

To compensate for these limitations, management presents non-GAAP financial measures in connection with GAAP results. Sapiens urges investors to review the reconciliation of its non-GAAP financial measures to the comparable GAAP financial measures, which it includes in press releases announcing quarterly financial results, including this press release, and not to rely on any single financial measure to evaluate the Company’s business.

 

2

 

 

Reconciliation tables of the most comparable GAAP financial measures to the non-GAAP financial measures used in this press release are included with the financial tables of this release.

 

The Company defines Adjusted EBITDA as net profit, adjusted for valuation adjustment on acquired deferred revenue, stock-based compensation expense, depreciation and amortization, capitalized of software development costs, compensation expenses related to acquisition and acquisition-related costs, restructuring and cost reduction costs, financial expense (income), provision for income taxes and other income (expenses). These amounts are often excluded by other companies to help investors understand the operational performance of their business.

 

The Company uses Adjusted EBITDA as a measurement of its operating performance, because it assists in comparing the operating performance on a consistent basis by removing the impact of certain non-cash and non-operating items. Adjusted EBITDA reflects an additional way of viewing aspects of the operations that the Company believes, when viewed with the GAAP results and the accompanying reconciliations to corresponding GAAP financial measures, provide a more complete understanding of factors and trends affecting its business. The Company uses Adjusted Free Cash-Flow as a measurement of its operating performance, and reconciles cash-flow from operating activities to Adjusted Free Cash-Flow, while reducing the amounts for capitalization of software development costs and capital expenditures. The Company adds back cash payments made for former acquisitions in respect of  future performance targets and retention criteria as determined upon acquisition date of the respective acquired company, which were included in the cash-flow from operating activities. We believe that Adjusted Free Cash-Flow is useful in evaluating our business, because Adjusted Free Cash-Flow reflects the cash surplus available to fund the expansion of our business.

 

About Sapiens

 

Sapiens International Corporation empowers insurers to succeed in an evolving industry. The company offers digital software platforms, solutions and services for the property and casualty, life, pension and annuity, reinsurance, financial and compliance, workers’ compensation and financial markets. With more than 35 years of experience delivering to more than 600 organizations globally, Sapiens has a proven ability to satisfy customers’ core, data and digital requirements. For more information: www.sapiens.com.

 

3

 

 

Forward Looking Statements

 

Certain matters discussed in this press release that are incorporated herein and therein by reference are forward-looking statements within the meaning of Section 27A of the Securities Act, Section 21E of the Exchange Act and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, that are based on our beliefs, assumptions and expectations, as well as information currently available to us. Such forward-looking statements may be identified by the use of the words “anticipate,” “believe,” “estimate,” “expect,” “may,” “will,” “plan” and similar expressions. Such statements reflect our current views with respect to future events and are subject to certain risks and uncertainties. There are important factors that could cause our actual results, levels of activity, performance or achievements to differ materially from the results, levels of activity, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to: the COVID-19 (coronavirus) pandemic, which may last longer than expected and materially adversely affect our results of operations; the degree of our success in our plans to leverage our global footprint to grow our sales; the degree of our success in integrating the companies that we have acquired through the implementation of our M&A growth strategy; the lengthy development cycles for our solutions, which may frustrate our ability to realize revenues and/or profits from our potential new solutions; our lengthy and complex sales cycles, which do not always result in the realization of revenues; the degree of our success in retaining our existing customers or competing effectively for greater market share; difficulties in successfully planning and managing changes in the size of our operations; the frequency of the long-term, large, complex projects that we perform that involve complex estimates of project costs and profit margins, which sometimes change mid-stream; the challenges and potential liability that heightened privacy laws and regulations pose to our business; occasional disputes with clients, which may adversely impact our results of operations and our reputation; various intellectual property issues related to our business; potential unanticipated product vulnerabilities or cybersecurity breaches of our or our customers’ systems; risks related to the insurance industry in which our clients operate; risks associated with our global sales and operations, such as changes in regulatory requirements, wide-spread viruses and epidemics like the recent novel coronavirus outbreak, or fluctuations in currency exchange rates; and risks related to our principal location in Israel and our status as a Cayman Islands company.

 

While we believe such forward-looking statements are based on reasonable assumptions, should one or more of the underlying assumptions prove incorrect, or these risks or uncertainties materialize, our actual results may differ materially from those expressed or implied by the forward-looking statements. Please read the risks discussed under the heading “Risk Factors” in our most recent Annual Report on Form 20-F, in order to review conditions that we believe could cause actual results to differ materially from those contemplated by the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or will occur. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason, to conform these statements to actual results or to changes in our expectations.

 

Investors and Media Contact

Sapiens

Daphna Golden

Vice President, Head of Investor Relations

Email: ir@sapiens.com

4

 

 

SAPIENS INTERNATIONAL CORPORATION N.V. AND ITS SUBSIDIARIES

 

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

U.S. dollars in thousands (except per share amounts)

 

   Three months ended 
   March 31, 
   2021   2020 
   (unaudited)   (unaudited) 
         
Revenue   109,592    90,534 
Cost of revenue   65,336    54,270 
           
Gross profit   44,256    36,264 
           
Operating expenses:          
Research and development, net   13,088    10,526 
Selling, marketing, general and administrative   18,803    15,460 
Total operating expenses   31,891    25,986 
           
Operating income   12,365    10,278 
           
Financial and other expenses, net   515    1,487 
Taxes on income   1,948    1,901 
           
Net income   9,902    6,890 
           
Attributed to non-controlling interest   67    70 
           
Net income attributable to Sapiens’ shareholders   9,835    6,820 
Basic earnings per share   0.18    0.14 
           
Diluted earnings per share   0.18    0.13 
           
Weighted average number of shares outstanding used to compute basic earnings per share (in thousands)   54,689    50,175 
           
Weighted average number of shares outstanding used to compute diluted earnings per share (in thousands)   55,567    51,083 

 

5

 

 

SAPIENS INTERNATIONAL CORPORATION N.V. AND ITS SUBSIDIARIES

 

CONDENSED CONSOLIDATED NON-GAAP STATEMENTS OF INCOME

U.S. dollars in thousands (except per share amounts)

 

   Three months ended 
   March 31, 
   2021   2020 
   (unaudited)   (unaudited) 
         
Revenue   110,222    90,534 
Cost of revenue   60,993    50,743 
           
Gross profit   49,229    39,791 
           
Operating expenses:          
Research and development, net   14,720    11,963 
Selling, marketing, general and administrative   15,509    13,214 
Total operating expenses   30,229    25,177 
           
Operating income   19,000    14,614 
           
Financial and other expenses, net   515    1,487 
Taxes on income   3,510    2,645 
           
Net income   14,975    10,482 
           
Attributable to non-controlling interest   67    70 
           
Net income attributable to Sapiens’ shareholders   14,908    10,412 
           
Basic earnings per share   0.27    0.21 
           
Diluted earnings per share   0.27    0.20 
           
Weighted average number of shares outstanding used to compute basic earnings per share (in thousands)   54,689    50,175 
           
Weighted average number of shares outstanding used to compute diluted earnings per share (in thousands)   55,567    51,083 

 

6

 

 

SAPIENS INTERNATIONAL CORPORATION N.V. AND SUBSIDIARIES

 

RECONCILIATION OF GAAP TO NON-GAAP RESULTS

U.S. dollars in thousands (except per share amounts)

 

   Three months ended 
   March 31, 
   2021   2020 
   (unaudited)   (unaudited) 
         
GAAP revenue   109,592    90,534 
Valuation adjustment on acquired deferred revenue   630    - 
Non-GAAP revenue   110,222    90,534 
           
GAAP gross profit   44,256    36,264 
Revenue adjustment   630    - 
Amortization of capitalized software   1,784    1,496 
Amortization of other intangible assets   2,559    2,031 
Non-GAAP gross profit   49,229    39,791 
           
GAAP operating income   12,365    10,278 
Gross profit adjustments   4,973    3,527 
Capitalization of software development   (1,632)   (1,437)
Amortization of other intangible assets   1,366    589 
Stock-based compensation   1,399    622 
Acquisition-related costs *)   529    1,035 
Non-GAAP operating income   19,000    14,614 
           
GAAP net income attributable to Sapiens’ shareholders   9,835    6,820 
Operating income adjustments   6,635    4,336 
Taxes on income   (1,562)   (744)
Non-GAAP net income attributable to Sapiens’   shareholders   14,908    10,412 

 

(*) Acquisition-related costs pertain to charges on behalf of M&A agreements related to future performance targets and retention criteria, as well as third-party services, such as, tax, accounting and legal rendered until the acquisition date.

7

 

 

Summary of NON-GAAP Financial Information
U.S. dollars in thousands (except per share amounts)

 

   Q1 2021   Q4 2020    Q3 2020   Q2 2020   Q1 2020 
                     
Revenues   110,222    102,936    97,968    93,063    90,534 
Gross profit   49,229    47,044    44,206    41,900    39,791 
Operating income   19,000    18,666    17,859    16,783    14,614 
Net income to Sapiens’ shareholders   14,908    14,461    13,746    13,340    10,412 
Adjusted EBITDA   20,120    20,032    19,010    17,854    15,724 
                          
Basic earnings per share   0.27    0.27    0.27    0.27    0.21 
Diluted earnings per share   0.27    0.27    0.27    0.26    0.20 

 

Non-GAAP Revenues by Geographic Breakdown
U.S. dollars in thousands

 

   Q1 2021    Q4 2020    Q3 2020    Q2 2020    Q1 2020  
                     
North America   44,754    47,303    49,979    46,610    44,567 
Europe   57,642    49,225    42,394    41,030    40,232 
Rest of the world   7,826    6,408    5,595    5,423    5,735 
                          
Total   110,222    102,936    97,968    93,063    90,534 

 

Adjusted Free Cash-Flow

U.S. dollars in thousands

 

   Q1 2021    Q4 2020    Q3 2020    Q2 2020    Q1 2020  
                     
Cash-flow from operating activities   11,755    21,030    16,705    14,761    5,759 
Increase in capitalized software development costs   (1,632)   (1,604)   (1,506)   (1,251)   (1,437)
Capital expenditures   (821)   (725)   (963)   (393)   (552)
Free cash-flow   9,302    18,701    14,236    13,117    3,770 
                          
Cash payments attributed to acquisition-related costs(*) (**)   1,280    2,363    242    1,562    737 
                          
Adjusted free cash-flow   10,582    21,064    14,478    14,679    4,507 

 

(*)Included in cash-flow from operating activities

 

(**)Acquisition-related payments pertain to payments on behalf of M&A agreements related to future performance targets and retention criteria, as well as third-party services, such as, tax, accounting and legal rendered until the acquisition date.

8

 

 

Adjusted EBITDA Calculation
U.S. dollars in thousands

 

   Three months ended 
   March 31, 
   2021   2020 
   (unaudited)   (unaudited) 
         
GAAP operating income   12,365    10,278 
           
Non-GAAP adjustments:          
Valuation adjustment on acquired deferred revenue   630    - 
Amortization of capitalized software   1,784    1,496 
Amortization of other intangible assets   3,925    2,620 
Capitalization of software development   (1,632)   (1,437)
Stock-based compensation   1,399    622 
Compensation related to acquisition and acquisition-related costs   529    1,035 
           
Non-GAAP operating income   19,000    14,614 
           
Depreciation   1,120    1,110 
           
Adjusted EBITDA   20,120    15,724 

 

9

 

 

SAPIENS INTERNATIONAL CORPORATION N.V. AND ITS SUBSIDIARIES

 

CONDENSED CONSOLIDATED BALANCE SHEETS

U.S. dollars in thousands

 

   March 31,   December 31, 
   2021   2020 
   (unaudited)   (unaudited) 
         
ASSETS        
         
CURRENT ASSETS        
Cash and cash equivalents   142,184    152,561 
Short-term bank deposit   30,000    30,000 
Trade receivables, net and unbilled receivables   74,762    65,409 
Other receivables and prepaid expenses   16,494    19,388 
           
Total current assets   263,440    267,358 
           
LONG-TERM ASSETS          
Property and equipment, net   16,585    16,970 
Severance pay fund   6,604    6,582 
Goodwill and intangible assets, net   352,130    363,597 
Operating lease right-of-use assets   51,716    54,390 
Other long-term assets   6,078    5,264 
           
Total long-term assets   433,113    446,803 
           
TOTAL ASSETS   696,553    714,161 
           
LIABILITIES AND EQUITY          
           
CURRENT LIABILITIES          
Trade payables   6,057    5,389 
Current maturities of Series B Debentures   19,796    19,796 
Accrued expenses and other liabilities   68,750    75,119 
Current maturities of operating lease liabilities   10,719    9,924 
Deferred revenue   41,470    34,548 
           
Total current liabilities   146,792    144,776 
           
LONG-TERM LIABILITIES          
Series B Debentures, net of current maturities   78,906    98,676 
Deferred tax liabilities   14,704    16,010 
Other long-term liabilities   13,037    12,129 
Long-term operating lease liabilities   46,531    48,773 
Redeemable non-controlling interest   562    517 
Accrued severance pay   9,530    9,586 
           
Total long-term liabilities   163,270    185,691 
           
EQUITY   386,491    383,694 
           
TOTAL LIABILITIES AND EQUITY   696,553    714,161 

 

10

 

 

SAPIENS INTERNATIONAL CORPORATION N.V. AND ITS SUBSIDIARIES

 

CONSOLIDATED STATEMENT OF CASH FLOW
U.S. dollars in thousands

 

   For the three months ended
March 31,
 
   2021   2020 
   (unaudited)   (unaudited) 
Cash flows from operating activities:        
Net income   9,902    6,890 
Reconciliation of net income to net cash provided by operating activities:          
Depreciation and amortization   6,829    5,226 
Accretion of discount on Series B Debentures   26    33 
Stock-based compensation related to options issued to employees   1,399    622 
Capital loss from sale of property and equipment   5    - 
           
Net changes in operating assets and liabilities, net of amount acquired:          
Trade receivables, net and unbilled receivables   (10,541)   (9,009)
Deferred tax assets, net   (1,913)   (1,257)
Other operating assets   6,116    2,260 
Trade payables   609    (52)
Other operating liabilities   (7,774)   (759)
Deferred revenues   6,995    1,655 
Accrued severance pay, net   102    150 
           
Net cash provided by operating activities   11,755    5,759 
           
Cash flows from investing activities:          
Purchase of property and equipment   (821)   (552)
Investment in deposit   -    (665)
Proceeds from restricted deposit used for completed acquisition   -    22,890 
Payments for business acquisitions, net of cash acquired   -    (22,061)
Proceeds from sale of property and equipment   154    - 
Capitalized software development costs   (1,632)   (1,437)
           
Net cash used in investing activities   (2,299)   (1,825)
           
Cash flows from financing activities:          
Proceeds from employee stock options exercised   413    600 
Repayment of Series B Debenture   (19,796)   (9,898)
Receipt of short-term loan   -    20,000 
Payment of contingent considerations   (537)   (538)
Dividend to non-controlling interest   (31)   - 
           
Net cash provided by (used in) financing activities   (19,951)   10,164 
           
Effect of exchange rate changes on cash and cash equivalents   118    (836)
           
Increase (decrease) in cash and cash equivalents   (10,377)   13,262 
Cash and cash equivalents at the beginning of period   152,561    66,295 
           
Cash and cash equivalents at the end of period   142,184    79,557 

 

11

 

 

Debentures Covenants

 

As of March 31, 2021, Sapiens was in compliance with all of its financial covenants under the indenture for the Series B Debentures, based on having achieved the following in its consolidated financial results:

 

Covenant 1

   
§Target shareholders’ equity (excluding minority interest): above $120 million.
§Actual shareholders’ equity (excluding minority interest) equal to $384 million.

 

Covenant 2

   
§Target ratio of net financial indebtedness to net capitalization (in each case, as defined under the indenture for the Company’s Series B Debentures) below 65%.
§Actual ratio of net financial indebtedness to net capitalization equal to (22.55)%.

 

Covenant 3

   
§Target ratio of net financial indebtedness to EBITDA (accumulated calculation for the four last quarters) is below 5.5.
§Actual ratio of net financial indebtedness to EBITDA (accumulated calculation for the four last quarters) is equal to (0.92).

 

12